)| PMID |
19118282 ( ) |
|---|---|
| Title | A new look at the eye: aldosterone and mineralocorticoid receptors as novel targets in retinal vasculopathy. |
| Abstract |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 12680 | VEGFA | vascular endothelial growth factor A | 10 | VEGF | vascular endothelial growth factor | |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | 8 | glucose 6 phosphate dehydrogenase g6pd | G6PD | |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | 8 | angiotensinogen | ang ii | Ang | |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | 7 | nadph oxidase | |
| 7891 | NOX4 | NADPH oxidase 4 | 5 | Nox4 | |
| 9958 | REN | renin | 4 | renin | |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | 3 | Nox2 | |
| 7660 | NCF1 | neutrophil cytosolic factor 1, (chronic granulomatous disease, autosomal 1) | 2 | p47phox | |
| 2707 | ACE | angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 | 2 | angiotensin converting enzyme | |
| 2577 | CYBA | cytochrome b-245, alpha polypeptide | 2 | p22phox | |
| 7661 | NCF2 | neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) | 1 | p67phox | |
| 10618 | CCL2 | chemokine (C-C motif) ligand 2 | 1 | monocyte chemoattractant protein 1 | |
| 2592 | CYP11B2 | cytochrome P450, family 11, subfamily B, polypeptide 2 | 1 | aldosterone synthase | |
| 5464 | IGF1 | insulin-like growth factor 1 (somatomedin C) | 1 | insulin like growth factor 1 | |
| 5208 | HSD11B1 | hydroxysteroid (11-beta) dehydrogenase 1 | 1 | hsd1 | |
| 18305 | ATP6AP2 | ATPase, H+ transporting, lysosomal accessory protein 2 | 1 | renin receptor | |
| 9393 | PRKCA | protein kinase C, alpha | 1 | protein kinase c | |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | 1 | interleukin 6 | |
| 7662 | NCF4 | neutrophil cytosolic factor 4, 40kDa | 1 | p40phox | |
| 7979 | NR3C2 | nuclear receptor subfamily 3, group C, member 2 | 1 | mineralocorticoid receptor | |
| 11765 | TGFA | transforming growth factor, alpha | 1 | transforming growth factor | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | Activated MR inhibits G6PD and increases Nox4-based NADPH oxidase localized in the plasma membrane |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | of ROS (oxidative oxidative stress stimulates redox-sensitive pathways possibly involving VEGF to promote angiogenesis inflammation and fibrosis which underlie retinal vasculopathy |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 1.2 | Key Words Nox4 _amp_#149 G6PD _amp_#149 angiogenesis _amp_#149 spironolactone |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | Key Words Nox4 _amp_#149 G6PD _amp_#149 angiogenesis _amp_#149 spironolactone |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | vascular permeability and angiogenesis is vascular endothelial growth factor (VEGF), VEGF which signals through protein kinase C mitogen-activated protein kinases and |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | mitogen-activated protein kinases and reactive oxygen species (ROS) ROS through VEGF receptor 1 (fms-like fms-like tyrosine kinase-1 and VEGF receptor 2 |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | ROS through VEGF receptor 1 (fms-like fms-like tyrosine kinase-1 and VEGF receptor 2 (fetal fetal liver kinase-1 |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | VEGF expression is increased by glucose advanced glycation end products transforming |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | Blocking effects of VEGF with intravitreal anti-VEGF drugs such as pegaptanib ranibizumab and bevacizumab |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | Moreover VEGF is pleiotropic affecting a broad spectrum of endothelial neuronal and |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Ang | 2.0 | more effective in treating retinal vasculopathy especially because angiotensin (Ang) Ang II and aldosterone are proinflammatory fibrogenic and angiogenic and because |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Ang | 2.0 | Renin angiotensin-converting enzyme angiotensinogen Ang II and Ang II receptors have been shown at the |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Ang | 2.0 | Renin angiotensin-converting enzyme angiotensinogen Ang II and Ang II receptors have been shown at the mRNA and protein |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Ang | 2.0 | that interruption of the RAS with angiotensin-converting enzyme inhibitors or Ang II type 1 (AT AT 1 receptor (AT AT 1 |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | aldosterone increases proliferation and tubulogenesis to a similar magnitude as VEGF and that this is associated with activation of the MR |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | aldosterone influences redox state are downregulation of glucose-6-phosphate dehydrogenase (G6PD), G6PD which is a major source of reduced NAD(P)H, NAD P |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | Wilkinson-Berka et al demonstrated that aldosterone decreases G6PD mRNA expression in retinal endothelial cells and that retinal nicotinamide |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 0.0 | phosphate reduced oxidase 4 (NADPH NADPH oxidase Nox 4 a Nox2 homolog is upregulated in oxygen-induced retinopathy ( Figure |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 1.2 | In oxygen-induced retinopathy Nox4 expression was increased especially in the presence of aldosterone and |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 1.2 | Nox4 is expressed in nonphagocytic cells including vascular endothelium is localized |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 0.0 | vascular endothelium is localized to the endoplasmic reticulum and unlike Nox2 it only requires p22phox and not p47phox p40phox or p67phox |
| 2577 | CYBA | cytochrome b-245, alpha polypeptide | p22phox | 0.0 | to the endoplasmic reticulum and unlike Nox2 it only requires p22phox and not p47phox p40phox or p67phox for its activation |
| 7660 | NCF1 | neutrophil cytosolic factor 1, (chronic granulomatous disease, autosomal 1) | p47phox | 0.0 | reticulum and unlike Nox2 it only requires p22phox and not p47phox p40phox or p67phox for its activation |
| 7662 | NCF4 | neutrophil cytosolic factor 4, 40kDa | p40phox | 0.0 | and unlike Nox2 it only requires p22phox and not p47phox p40phox or p67phox for its activation |
| 7661 | NCF2 | neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) | p67phox | 0.0 | Nox2 it only requires p22phox and not p47phox p40phox or p67phox for its activation |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 1.2 | Of the Nox proteins Nox4 has been shown to be strongly proangiogenic possibly through upregulation |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.5 | been shown to be strongly proangiogenic possibly through upregulation of VEGF signaling |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 0.0 | Nox2 p22phox and p47phox classic subunits of NADPH oxidase have also |
| 2577 | CYBA | cytochrome b-245, alpha polypeptide | p22phox | 0.0 | Nox2 p22phox and p47phox classic subunits of NADPH oxidase have also been |
| 7660 | NCF1 | neutrophil cytosolic factor 1, (chronic granulomatous disease, autosomal 1) | p47phox | 0.0 | Nox2 p22phox and p47phox classic subunits of NADPH oxidase have also been implicated in |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | Moreover the fact that retinal gene expression of G6PD is reduced and that of Nox4 is increased does not |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 1.2 | retinal gene expression of G6PD is reduced and that of Nox4 is increased does not necessarily mean that protein levels are |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | G6PD | 3.4 | mean that protein levels are changed nor that activity of G6PD or NADPH oxidase is altered |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | activated mr inhibits g6pd and increases nox4 based nadph oxidase localized in the plasma membrane and endoplasmic reticulum er to generate the ros superoxide o[ 2] and h 2 o 2 . |
| 7979 | NR3C2 | nuclear receptor subfamily 3, group C, member 2 | mineralocorticoid receptor | 1.0 | here we learn that similar to what has been suggested in the heart brain and vasculature the eye has a dynamic aldosterone mineralocorticoid receptor mr system that plays an important pathophysiological role in the development of retinal vasculopathy. |
| 9393 | PRKCA | protein kinase C, alpha | protein kinase c | 1.0 | among the many factors that have been implicated in vascular permeability and angiogenesis is vascular endothelial growth factor vegf which signals through protein kinase c mitogen activated protein kinases and reactive oxygen species ros through vegf receptor 1 fms like tyrosine kinase 1 and vegf receptor 2 fetal liver kinase 1 . |
| 12680 | VEGFA | vascular endothelial growth factor A | vascular endothelial growth factor | 1.0 | among the many factors that have been implicated in vascular permeability and angiogenesis is vascular endothelial growth factor vegf which signals through protein kinase c mitogen activated protein kinases and reactive oxygen species ros through vegf receptor 1 fms like tyrosine kinase 1 and vegf receptor 2 fetal liver kinase |
| 5464 | IGF1 | insulin-like growth factor 1 (somatomedin C) | insulin like growth factor 1 | 1.0 | vegf expression is increased by glucose advanced glycation end products transforming growth factor b and insulin like growth factor 1 all of which are modulated by the renin angiotensin aldosterone system. |
| 9958 | REN | renin | renin | 1.0 | vegf expression is increased by glucose advanced glycation end products transforming growth factor b and insulin like growth factor 1 all of which are modulated by the renin angiotensin aldosterone system. |
| 11765 | TGFA | transforming growth factor, alpha | transforming growth factor | 1.0 | vegf expression is increased by glucose advanced glycation end products transforming growth factor b and insulin like growth factor 1 all of which are modulated by the renin angiotensin aldosterone system. |
| 9958 | REN | renin | renin | 1.0 | this raises the possibility that targeting upstream regulatory systems such as the renin angiotensin aldosterone system may be more effective in treating retinal vasculopathy especially because angiotensin ang ii and aldosterone are proinflammatory fibrogenic and angiogenic and because t |
| 9958 | REN | renin | renin | 1.0 | treating retinal vasculopathy especially because angiotensin ang ii and aldosterone are proinflammatory fibrogenic and angiogenic and because the eye possesses a functionally active local intracrine renin angiotensin system ras . |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | ang ii | 1.0 | aises the possibility that targeting upstream regulatory systems such as the renin angiotensin aldosterone system may be more effective in treating retinal vasculopathy especially because angiotensin ang ii and aldosterone are proinflammatory fibrogenic and angiogenic and because the eye possesses a functionally active local intracrine renin angiotensin system ras . |
| 9958 | REN | renin | renin | 1.0 | renin angiotensin converting enzyme angiotensinogen ang ii and ang ii receptors have been shown at the mrna and protein levels in humans rats and rabbits in the vasculature neurons and glia. |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | ang ii | 1.0 | renin angiotensin converting enzyme angiotensinogen ang ii and ang ii receptors have been shown at the mrna and protein levels in humans rats and rabbits in the vasculature neurons and glia. |
| 2707 | ACE | angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 | angiotensin converting enzyme | 1.0 | renin angiotensin converting enzyme angiotensinogen ang ii and ang ii receptors have been shown at the mrna and protein levels in humans rats and rabbits in the vasculature neurons and glia. |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | angiotensinogen | 1.0 | renin angiotensin converting enzyme angiotensinogen ang ii and ang ii receptors have been shown at the mrna and protein levels in humans rats and rabbits in the vasculature neurons and glia. |
| 333 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | ang ii | 1.0 | experimental studies and clinical observations demonstrated that interruption of the ras with angiotensin converting enzyme inhibitors or ang ii type 1 at 1 receptor at 1 r blockers ameliorating many of the vascular abnormalities that develop in diabetic retinopathy and retinopathy of prematurity. |
| 2707 | ACE | angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 | angiotensin converting enzyme | 1.0 | experimental studies and clinical observations demonstrated that interruption of the ras with angiotensin converting enzyme inhibitors or ang ii type 1 at 1 receptor at 1 r blockers ameliorating many of the vascular abnormalities that develop in diabetic retinopathy and retinopathy of prematurity. |
| 18305 | ATP6AP2 | ATPase, H+ transporting, lysosomal accessory protein 2 | renin receptor | 1.0 | prorenin has also been implicated in retinal vascular injury because handle region peptide which binds to pro renin receptor as a decoy peptide and inhibits the nonproteolytic activation of prorenin inhibited retinal neovascularization in mice with oxygen induced retinopathy. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | licated in volume homeostasis and na balance is now recognized to be a potent profibrotic and proinflammatory mediator in the heart vasculature and kidneys with effects mediated through activation of nadph oxidase and increased generation of ros oxidative stress . |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | interleukin 6 | 1.0 | ltiple signaling molecules including mitogen activated protein kinases protein tyrosine phosphatases tyrosine kinases ion channels and proinflammatory genes such as monocyte chemoattractant protein 1 interleukin 6 and nuclear factor kappab. |
| 10618 | CCL2 | chemokine (C-C motif) ligand 2 | monocyte chemoattractant protein 1 | 1.0 | gh redox sensitive regulation of multiple signaling molecules including mitogen activated protein kinases protein tyrosine phosphatases tyrosine kinases ion channels and proinflammatory genes such as monocyte chemoattractant protein 1 interleukin 6 and nuclear factor kappab. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | ong the various mechanisms through which aldosterone influences redox state are downregulation of glucose 6 phosphate dehydrogenase g6pd which is a major source of reduced nad p h and upregulation of nadph oxidase a key enzyme involved in vascular ros generation. |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | glucose 6 phosphate dehydrogenase | 1.0 | among the various mechanisms through which aldosterone influences redox state are downregulation of glucose 6 phosphate dehydrogenase g6pd which is a major source of reduced nad p h and upregulation of nadph oxidase a key enzyme involved in vascular ros generation. |
| 4057 | G6PD | glucose-6-phosphate dehydrogenase | glucose 6 phosphate dehydrogenase g6pd | 1.0 | among the various mechanisms through which aldosterone influences redox state are downregulation of glucose 6 phosphate dehydrogenase g6pd which is a major source of reduced nad p h and upregulation of nadph oxidase a key enzyme involved in vascular ros generation. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | wilkinson berka et al demonstrated that aldosterone decreases g6pd mrna expression in retinal endothelial cells and that retinal nicotinamide adenine dinucleotide phosphate reduced oxidase 4 nadph oxidase [nox]4 a nox2 homolog is upregulated in oxygen induced retinopathy figure . |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | growing evidence indicates an important role for nadph oxidase in retinal vascular inflammation. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | nox2 p22phox and p47phox classic subunits of nadph oxidase have also been implicated in nadph oxidase derived ros in vascular retinopathy. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | moreover the fact that retinal gene expression of g6pd is reduced and that of nox4 is increased does not necessarily mean that protein levels are changed nor that activity of g6pd or nadph oxidase is altered. |
| 2592 | CYP11B2 | cytochrome P450, family 11, subfamily B, polypeptide 2 | aldosterone synthase | 1.0 | wilkinson berka et al suggest that this may be so because genes for the enzymes responsible for aldosterone synthesis namely 11b hydroxysteroid dehydrogenase type 1 11b hsd1 11b hsd2 and aldosterone synthase are expressed in retina. |
| 5208 | HSD11B1 | hydroxysteroid (11-beta) dehydrogenase 1 | hsd1 | 1.0 | wilkinson berka et al suggest that this may be so because genes for the enzymes responsible for aldosterone synthesis namely 11b hydroxysteroid dehydrogenase type 1 11b hsd1 11b hsd2 and aldosterone synthase are expressed in retina. |